These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical practice: combination antifungal therapy for mold infections: much ado about nothing? Vazquez JA Clin Infect Dis; 2008 Jun; 46(12):1889-901. PubMed ID: 18466092 [TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility testing in fungi: a global perspective on a variety of methods. Lass-Flörl C; Perkhofer S; Mayr A Mycoses; 2010 Jan; 53(1):1-11. PubMed ID: 20078786 [TBL] [Abstract][Full Text] [Related]
4. Combination antifungal therapy: the new frontier. Vazquez JA Future Microbiol; 2007 Apr; 2(2):115-39. PubMed ID: 17661650 [TBL] [Abstract][Full Text] [Related]
5. Fungal spectrum identified by a new slide culture and in vitro drug susceptibility using Etest in fungal keratitis. Qiu WY; Yao YF; Zhu YF; Zhang YM; Zhou P; Jin YQ; Zhang B Curr Eye Res; 2005 Dec; 30(12):1113-20. PubMed ID: 16354625 [TBL] [Abstract][Full Text] [Related]
6. Changing epidemiology of systemic fungal infections. Richardson M; Lass-Flörl C Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126 [TBL] [Abstract][Full Text] [Related]
7. Natural products and antifungal drug discovery. Jacob MR; Walker LA Methods Mol Med; 2005; 118():83-109. PubMed ID: 15888937 [TBL] [Abstract][Full Text] [Related]
8. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Chamilos G; Kontoyiannis DP Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387 [TBL] [Abstract][Full Text] [Related]
9. Prevention of fungal infections in the immunocompromised host. Mahfouz T; Anaissie E Curr Opin Investig Drugs; 2003 Aug; 4(8):974-90. PubMed ID: 14508882 [TBL] [Abstract][Full Text] [Related]
11. [Current status of studies on sensitivity to antifungal agents]. Martín Mazuelos E Enferm Infecc Microbiol Clin; 1992; 10(6):366-71. PubMed ID: 1391021 [No Abstract] [Full Text] [Related]
12. Susceptibility testing methods of antifungal agents. Ernst EJ Methods Mol Med; 2005; 118():3-12. PubMed ID: 15888930 [TBL] [Abstract][Full Text] [Related]
13. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Kanafani ZA; Perfect JR Clin Infect Dis; 2008 Jan; 46(1):120-8. PubMed ID: 18171227 [TBL] [Abstract][Full Text] [Related]
14. Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. Guarro J J Antimicrob Chemother; 2011 Jul; 66(7):1447-66. PubMed ID: 21493649 [TBL] [Abstract][Full Text] [Related]
15. Combination antifungal therapy: a critical review of the evidence. Ostrosky-Zeichner L Clin Microbiol Infect; 2008 May; 14 Suppl 4():65-70. PubMed ID: 18430131 [TBL] [Abstract][Full Text] [Related]
16. [Antifungal drug resistance: mechanisms of resistance, freqeuncy, prevention and control of resistance]. Mitrović SM; Dzamić AM; Arsić-Arsenijević VS; Radonjić IV; Kranjcić-Zec IF Srp Arh Celok Lek; 2007; 135(7-8):486-94. PubMed ID: 17929545 [TBL] [Abstract][Full Text] [Related]
17. [Fungal infections in patients with ARC with or without AIDS. Evaluation of the chemosensitivity of the isolated strains]. Michelone G; Cavanna C; Gramegna G; Maccabruni A; Lombardi G G Ital Chemioter; 1987; 34(1-3):23-7. PubMed ID: 3504411 [No Abstract] [Full Text] [Related]
18. [Fungal infections--diagnosis, pathogens and therapy]. Willinger B Wien Med Wochenschr; 2007; 157(19-20):530-2. PubMed ID: 18030560 [No Abstract] [Full Text] [Related]